UMMMY22027 // Selinexor // Lipe
Basic Study Information
Purpose:Location: University of Rochester
Selinexor is a drug that has been approved in the treatment of patients with symptomatic
multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma
remains observation, but there are numerous clinical trials investigating interventions
to delay progression to multiple myeloma and prevent or delay disease related outcomes.
A subset of patients with intermediate or high risk smoldering multiple myeloma have
a much higher risk of progressive to multiple myeloma, while the low risk smoldering
myeloma patient population has a much lower risk. This is a clinical trial investigating
the use of low-dose selinexor in patients with intermediate to high-risk smoldering
multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate
to high risk smoldering myeloma patients will help to delay progression of disease
to symptomatic multiple myeloma.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search